Cargando…
Diarylethene‐Based Photoswitchable Inhibitors of Serine Proteases
A bicyclic peptide scaffold was chemically adapted to generate diarylethene‐based photoswitchable inhibitors of serine protease Bos taurus trypsin 1 (T1). Starting from a prototype molecule—sunflower trypsin inhibitor‐1 (SFTI‐1)—we obtained light‐controllable inhibitors of T1 with K(i) in the low na...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519022/ https://www.ncbi.nlm.nih.gov/pubmed/34268844 http://dx.doi.org/10.1002/anie.202108847 |
_version_ | 1784584362723901440 |
---|---|
author | Babii, Oleg Afonin, Sergii Diel, Christian Huhn, Marcel Dommermuth, Jennifer Schober, Tim Koniev, Serhii Hrebonkin, Andrii Nesterov‐Mueller, Alexander Komarov, Igor V. Ulrich, Anne S. |
author_facet | Babii, Oleg Afonin, Sergii Diel, Christian Huhn, Marcel Dommermuth, Jennifer Schober, Tim Koniev, Serhii Hrebonkin, Andrii Nesterov‐Mueller, Alexander Komarov, Igor V. Ulrich, Anne S. |
author_sort | Babii, Oleg |
collection | PubMed |
description | A bicyclic peptide scaffold was chemically adapted to generate diarylethene‐based photoswitchable inhibitors of serine protease Bos taurus trypsin 1 (T1). Starting from a prototype molecule—sunflower trypsin inhibitor‐1 (SFTI‐1)—we obtained light‐controllable inhibitors of T1 with K(i) in the low nanomolar range, whose activity could be modulated over 20‐fold by irradiation. The inhibitory potency as well as resistance to proteolytic degradation were systematically studied on a series of 17 SFTI‐1 analogues. The hydrogen bond network that stabilizes the structure of inhibitors and possibly the enzyme–inhibitor binding dynamics were affected by isomerization of the photoswitch. The feasibility of manipulating enzyme activity in time and space was demonstrated by controlled digestion of gelatin‐based hydrogel and an antimicrobial peptide BP100‐RW. Finally, our design principles of diarylethene photoswitches are shown to apply also for the development of other serine protease inhibitors. |
format | Online Article Text |
id | pubmed-8519022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85190222021-10-21 Diarylethene‐Based Photoswitchable Inhibitors of Serine Proteases Babii, Oleg Afonin, Sergii Diel, Christian Huhn, Marcel Dommermuth, Jennifer Schober, Tim Koniev, Serhii Hrebonkin, Andrii Nesterov‐Mueller, Alexander Komarov, Igor V. Ulrich, Anne S. Angew Chem Int Ed Engl Communications A bicyclic peptide scaffold was chemically adapted to generate diarylethene‐based photoswitchable inhibitors of serine protease Bos taurus trypsin 1 (T1). Starting from a prototype molecule—sunflower trypsin inhibitor‐1 (SFTI‐1)—we obtained light‐controllable inhibitors of T1 with K(i) in the low nanomolar range, whose activity could be modulated over 20‐fold by irradiation. The inhibitory potency as well as resistance to proteolytic degradation were systematically studied on a series of 17 SFTI‐1 analogues. The hydrogen bond network that stabilizes the structure of inhibitors and possibly the enzyme–inhibitor binding dynamics were affected by isomerization of the photoswitch. The feasibility of manipulating enzyme activity in time and space was demonstrated by controlled digestion of gelatin‐based hydrogel and an antimicrobial peptide BP100‐RW. Finally, our design principles of diarylethene photoswitches are shown to apply also for the development of other serine protease inhibitors. John Wiley and Sons Inc. 2021-08-25 2021-09-27 /pmc/articles/PMC8519022/ /pubmed/34268844 http://dx.doi.org/10.1002/anie.202108847 Text en © 2021 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Communications Babii, Oleg Afonin, Sergii Diel, Christian Huhn, Marcel Dommermuth, Jennifer Schober, Tim Koniev, Serhii Hrebonkin, Andrii Nesterov‐Mueller, Alexander Komarov, Igor V. Ulrich, Anne S. Diarylethene‐Based Photoswitchable Inhibitors of Serine Proteases |
title | Diarylethene‐Based Photoswitchable Inhibitors of Serine Proteases |
title_full | Diarylethene‐Based Photoswitchable Inhibitors of Serine Proteases |
title_fullStr | Diarylethene‐Based Photoswitchable Inhibitors of Serine Proteases |
title_full_unstemmed | Diarylethene‐Based Photoswitchable Inhibitors of Serine Proteases |
title_short | Diarylethene‐Based Photoswitchable Inhibitors of Serine Proteases |
title_sort | diarylethene‐based photoswitchable inhibitors of serine proteases |
topic | Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519022/ https://www.ncbi.nlm.nih.gov/pubmed/34268844 http://dx.doi.org/10.1002/anie.202108847 |
work_keys_str_mv | AT babiioleg diarylethenebasedphotoswitchableinhibitorsofserineproteases AT afoninsergii diarylethenebasedphotoswitchableinhibitorsofserineproteases AT dielchristian diarylethenebasedphotoswitchableinhibitorsofserineproteases AT huhnmarcel diarylethenebasedphotoswitchableinhibitorsofserineproteases AT dommermuthjennifer diarylethenebasedphotoswitchableinhibitorsofserineproteases AT schobertim diarylethenebasedphotoswitchableinhibitorsofserineproteases AT konievserhii diarylethenebasedphotoswitchableinhibitorsofserineproteases AT hrebonkinandrii diarylethenebasedphotoswitchableinhibitorsofserineproteases AT nesterovmuelleralexander diarylethenebasedphotoswitchableinhibitorsofserineproteases AT komarovigorv diarylethenebasedphotoswitchableinhibitorsofserineproteases AT ulrichannes diarylethenebasedphotoswitchableinhibitorsofserineproteases |